微创颅内血肿清除术与去骨瓣减压血肿清除术治疗急性期高血压脑出血的临床对比

Clinical Comparison of Minimally Invasive Removal of Intracranial Hematoma and Removal of Decompressive Craniectomy Hematoma in the Treatment of Hypertensive Cerebral Hemorrhage in Acute Stage

目的:探讨微创颅内血肿清除术与去骨瓣减压血肿清除术治疗急性期高血压脑出血的临床效果。方法:选取2014年3月-2015年5月在笔者所在医院接受手术治疗的急性期高血压脑出血患者,按照随机数表法将所有的患者分为观察组和对照组,各45例,观察组患者采用微创颅内血肿清除术治疗,对照组患者采用去骨瓣减压血肿清除术治疗,比较两组患者术后并发症发生率以及临床疗效。结果:治疗后,观察组患者的继发血肿、肺部感染、上消化道出血、尿道感染及电解质混乱等并发症的发生率(2.22%、4.44%、8.89%、6.67%、2.22%)明显低于对照组(13.33%、17.78%、26.67%、24.44%、22.22%),两组比较差异均有统计学意义(P<0.05);治疗后,观察组患者的总有效率(97.78%)明显的高于对照组(82.22%),两组比较差异有统计学意义(P<0.05)。结论:微创颅内血肿清除术治疗高血压脑出血术后并发症发生率比较低,并且临床效果显著,值得推广使用。

Objective： To explore the curative effect of minimally invasive removal of intracranial hematoma and decompressive craniectomy hematoma in the treatment of acute hypertensive cerebral hemorrhage.Method： From March 2014 to May 2015, the acute stage of hypertensive intracerebral hemorrhage patients admitted in our hospital were selected, according to the random number table method, all of the patients were divided into the observation group and the control group, 45 cases in each group, the observation group was treated by minimally invasive intracranial hematoma debridement, the control group was used craniotomy hematoma removal treatment, complications rate and clinical efficacy of the two groups were compared.Result： After treatment, secondary to hematoma, pulmonary infection, hemorrhage of upper digestive tract, urinary tract infection and electrolyte disorder complication incidence of the observation group（2.22%, 4.44% and 8.89%, 6.67%, 2.22%） were lower than the control group（13.33%, 17.78%, 26.67%, 24.44%, 22.22%）, the differences had significant（P〈0.05）.After treatment, the total efficiency of the observation group（97.78%） was higher than the control group（82.22%）, the difference had significant（P〈0.05）.Conclusion： The minimally invasive treatment of intracranial hematoma in patients with hypertensive cerebral hemorrhage is lower incidence of postoperative complications, and the clinical effect is significant, worthy of promotion of use.